Get Live Data

focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Destiny Pharma. Share Price
  4. Destiny Pharma. Share Regulatory News
  5. Result of Annual General Meeting

Pin to quick picksDestiny Pharma. Regulatory News (DEST)

Destiny Pharma. Information

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.50
Bid: 16.00
Ask: 17.00
Change: 0.00 (0.00%)
Spread: 1.00 (6.25%)
Open: 16.50
High: 16.50
Low: 16.50
Prev. Close: 16.50
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Annual General Meeting

25 May 2023 12:23

RNS Number : 6865A
Destiny Pharma PLC
25 May 2023
 

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

Result of Annual General Meeting

 

Brighton, United Kingdom - 25 May 2023 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that all resolutions proposed to shareholders at the Annual General Meeting held earlier today were duly passed.

 

The full text of each resolution was included in the notice of the meeting which was made available on the Company's website and posted to shareholders on 27 April 2023. The results for the resolutions will shortly be available on the Investors' section of the Company's website, www.destinypharma.com.

 

For further information, please contact: 

 

Destiny Pharma plc 

Dr Debra Barker, CEO 

Shaun Claydon, CFO 

+44 (0)1273 704 440 

pressoffice@destinypharma.com 

 

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0)20 7220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

Optimum Strategic Communications 

Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper

+44 (0) 203 922 0891

DestinyPharma@optimumcomms.com 

 

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

  

About Destiny Pharma

 

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

 

For further information on the Company, please visit https://www.destinypharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGAAMBTMTTTBBJ
12345
Date   Source Headline
7th Dec 20227:00 amRNSXF-73 Nasal final Phase 3 development plans
2nd Dec 20222:48 pmRNSDirector Disclosure
23rd Nov 20227:00 amRNSAppointment of Corporate Broker
21st Nov 20222:20 pmEQSDestiny Pharma PLC 'leads the world' in new approach to preventing hospital infections
18th Nov 20221:16 pmRNSDirector Shareholding Amendment
15th Nov 20227:00 amRNSXF-73 advances to clinically enabling safety study
31st Oct 202211:06 amRNSSecond Price Monitoring Extn
31st Oct 202211:01 amRNSPrice Monitoring Extension
22nd Sep 20227:00 amRNSNotice of R&D Update Meeting
8th Sep 20227:00 amRNSInterim results for six months ended 30 June 2022
7th Sep 20227:03 amRNSPresenting at HC Wainwright Investment Conference
7th Sep 20227:01 amRNSPositive update from EMA on NTCD-M3 Phase 3 plans
5th Sep 20222:15 pmRNSExpiry of Share Options
22nd Aug 20227:00 amRNSNotice of Interim Results
28th Jul 20227:00 amRNSChair’s Investor Update
26th Jul 20227:00 amRNSPublication of new data on NTCD-M3
19th Jul 20227:00 amRNSPositive update from US FDA on XF-73 Phase 3
12th Jul 20227:00 amRNSGrant from the Cystic Fibrosis Foundation
7th Jul 20227:00 amRNSPublication of XF-73 drug synergy data
5th Jul 20227:00 amRNSNew XF-73 research programme
8th Jun 20227:00 amRNSGrant of share options
27th May 202211:56 amRNSResult of Annual General Meeting & Strategy Update
26th May 20227:00 amRNSBoard Changes
12th May 20227:00 amRNSLandmark NTCD-M3 data to be presented at Anaerobe
3rd May 20227:00 amRNSDestiny Pharma appoints Dr Yuri Martina as CMO
27th Apr 20223:34 pmRNSPosting of Annual Report and Notice of AGM
26th Apr 20223:30 pmRNSDirector/PDMR Shareholding
12th Apr 20227:00 amRNSAudited results for year ended 31 December 2021
4th Apr 20222:45 pmRNSNotice of Results
4th Apr 20222:37 pmRNSNotification of Major Holdings
31st Mar 20227:00 amRNSTo present data at ECCMID Congress
28th Mar 202211:30 amRNSResult of General Meeting and Total Voting Rights
25th Mar 20227:00 amRNSResult of Open Offer
22nd Mar 202210:30 amRNSExercise of Options and Total Voting Rights
8th Mar 202212:30 pmRNSFundraising
8th Feb 20227:00 amRNSPositive feedback from EMA on XF-73 Nasal gel Ph 3
1st Feb 20224:11 pmRNSExercise of Options and Total Voting Rights
1st Feb 20227:00 amRNSPositive data in XF-73 Dermal study with NIAID
31st Jan 20222:30 pmRNSExercise of Options and Total Voting Rights
25th Jan 20227:00 amRNSGrant of share options
24th Jan 20227:00 amRNSClinical and commercial opportunity of NTCD-M3
21st Jan 20227:15 amRNSDestiny Pharma Lancet Report
17th Jan 20227:00 amRNSStrategy/Company/Ops Update
21st Dec 20214:35 pmRNSExercise of Options and Total Voting Rights
17th Dec 20219:46 amRNSGrant of share options
15th Nov 20212:26 pmRNSDirectorate Change
4th Nov 20217:00 amRNSSAB Member Prof. Gerding is Keynote at C.diff Conf
18th Oct 20217:00 amRNSStudy gives strong support for potential of XF-73
27th Sep 20213:18 pmRNSDirector/PDMR Shareholding
27th Sep 20217:00 amRNSExpansion of clinical pipeline
12345

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.